185 results about "Sulfonosine" patented technology

The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.

The invention discloses a temperature-sensitive magnetic sulfadimidine molecular imprinted adsorbent as well as a preparation method and application thereof, belonging to the technical field of preparation of environment functional materials. A gamma-Fe2O3/SiO2 magnetic composite material is prepared by using a sol-gel method and is subjected to vinyl modification by using 3-(methylacryloyloxy) trimethoxypropylsilane; with a vinyl-modified magnetic composite material (MPS (Modified Polystyrene)-gamma-Fe2O3/SiO2) as a substrate material, sulfadimidine as a template molecule, acrylamide as a functional monomer, N-isopropylacrylamide as a temperature-sensitive monomer, ethylene glycol-bis(methylacrylic acid) ester as a cross-linking agent and 2,2'-azobisisobutyronitrile as an initiator, a temperature-sensitive magnetic molecular imprinted polymer is prepared by using a free group polymerization process and is applied to selective recognition and separation of the sulfadimidine in an aqueous solution; and the obtained polymer has the advantages of remarkable heat and magnet stability, sensitive magnet and heat inducting effect, higher adsorption capacity, reversible adsorption/release function along with the temperature and remarkable recognition performance of a sulfadimidine molecule.

The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. 1 In the formula, R.sup.1 represents hydrogen atom, a halogen atom or cyano group; R.sup.2 and R.sup.3 are the same as or different from and each represents hydrogen atom, a C.sub.1-C.sub.4 lower alkyl group or a halogen atom; R.sup.4 represents hydrogen atom or a C.sub.1-C.sub.4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R.sup.1, R.sup.2 and R.sup.3 are hydrogen atoms, where both R.sup.2 and R.sup.3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R.sup.1 and R.sup.2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R.sup.1 is cyano group or a halogen atom, at least one of R.sup.2 and R.sup.3 should not be a hydrogen atom.

Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.

Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and/or various disorders or disease states.

The present invention aims to provide a novel low-molecular-weight compound having an orexin agonist activity, which is expected to be useful as a superior agent for the treatment or prophylaxis of narcolepsy. The present invention provides a compound showing superior orexin agonist activity which is represented by the formula (I)

wherein each symbol is as defined in the DESCRIPTION, and a pharmaceutically acceptable acid addition salt thereof, as well as an orexin agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

Processes for preparing amino alcohols or salts thereof and sulfonamide substituted alcohol compounds are provided. Desirably, the sulfonamide substituted alcohol compounds are heterocyclic sulfonamide trifluoroalkyl-substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl-substituted alcohol compounds.

The invention discloses novel N-4-phenylsulfonamido--N'-1-desoxy-(2-desoxy-2-substituted-amino)-beta-D-glucopyransoylthiocarbamide compounds with the general formula disclosed in the specification, which have the activity of inhibiting carbonic anhydrase and further achieve the effect of resisting tumor metastasis and invasion. The compounds structurally have the three active segments sulfamine, substituted glucosamine and thiocarbamide, and the three active segments and Zn<2+> ions in the carbonic anhydrase form coordinate bonds, thereby inhibiting the catalytic activity of the enzyme and performing the function of resisting tumor metastasis and invasion. Thus, the compounds have application potential in the aspect of antitumor drugs. In the general formula, R is defined in the specification.

The invention discloses a triphosgene method for synthesizing benzene sulphanilamide, the intermediate of glimepiride, a drug for Type ii Diabetes Mellitus. Triphosgene is slowly dropped into a solution which contains phenethylamine and 3-ethyl-4-methyl pyrroline ketone, at a controlled temperature, so that N-[2-(3-ethyl-4-methyl-2-oxidation-3-pyrroline-1-formylamino)ethyl]-benzene (3) is obtained; the product reacts with chlorosulfonic acid to generate sulfonated product; the sulfonated product reacts with ammonia water to generate crude product benzenesulfonamide; the crude product is refined through solvent treatment to generate fine product; the reaction formula is show in the specification. The triphosgene method is simple in technology, simple in operation and high in yield; compared with the conventional method of phosgene, the solid phosgene (triphosgene) method is safer and is convenient to operate.

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

The invention discloses a method and special immune affinity adsorbent for extracting quinolone compound and/or sulfonamide compound. The immune affinity adsorbent consists of a solid-phase carrier and Norfloxacin monoclonal antibody and/or sulfamethoxazole monoclonal antibody coupled with the carrier, wherein the Norfloxacin monoclonal antibody and the sulfamethoxazole monoclonal antibody are obtained by taking Norfloxacin hapten, sulfamethoxazole hapten and carrier protein conjugate as immunogen; the quinolone compound is at least one of the following 13 types of compounds: Ciprofloxacin, Norfloxacin, Pefloxacin, Ofloxacin, Enoxacin, Marbofloxacin, Lomefloxacin, Danofloxacin, Enrofloxacin, Sarafloxacin, Difloxacin, Oxolinic acid and Flumequine; and the sulfonamide compound is at least one of the following 6 types of compounds: sulfapyridine, sulfathiazole, sulphapyridine, sulfamethizole, sulfamonomethoxine and sulfamethoxazole.

The invention discloses a method for detecting sulfonamide and beta-lactam antibiotics in livestock and poultry breeding wastewater. The method comprises the following steps: sequentially centrifugingand filtering a to-be-detected water sample; adding deionized water into the obtained filtrate for dilution; adding Na2EDTA, adjusting the pH, carrying out solid-phase extraction treatment on the obtained pre-treated water sample, carrying out negative-pressure leaching treatment and normal-pressure elution treatment on a solid-phase extraction column subjected to the solid-phase extraction treatment, collecting eluent, and then carrying out nitrogen blowing and constant volume treatment to obtain an antibiotic solution to be detected; and carrying out antibiotic content detection on the antibiotic solution to be detected by adopting a high performance liquid chromatography-tandem mass spectrometry method. According to the detection method disclosed by the invention, a solid phase extraction-liquid chromatography tandem mass spectrometry method is adopted, and various process conditions and parameters are selected and determined, so that the detection method can be used for rapidly and accurately detecting antibiotics in water and detecting sulfonamide and beta-lactam antibiotics in the livestock and poultry breeding wastewater at the same time.

The invention provides a sulfonamide antibiotic synergistically degraded bacteria and an application thereof. The sulfonamide antibiotic synergistically degraded bacteria comprise arthrobacterium P27and nocardioides N27, wherein the arthrobacterium P27 is preserved in China General Microbiological Culture Collection Center on December 03, 2019, and the preservation number is CGMCC No. 19070; andthe nocardioides N27 is preserved in the China General Microbiological Culture Collection Center on December 03, 2019, and the preservation is CGMCC NO. 19071. According to the technical scheme, compounding of the two strains of bacteria can synergistically complete degradation of sulfamethoxazole and an azacyclo product 3-amino-5-methylisoxazole; and in addition, the strain P27 can degrade one side of benzene rings of various sulfonamide antibiotics, the degradation substrate spectrum is wide, and a new idea and a new strain resource are provided for deep removal of the sulfonamide antibiotics.

The invention provides a method for separating and measuring sulfonamide-class impurities in celecoxib through HPLC (High Performance Liquid Chromatography) and application. According to the chromatographic column of the high performance liquid chromatography, phenyl bonded silica gel is adopted as a stationary phase, and an inorganic acid-organic phase is adopted as a mobile phase to perform gradient elution; the temperature of the stationary phase ranges from 25 to 35 degrees Celsius, the flow rate of the stationary phase ranges from 0.9 to 1.1 mL/min, and the detection wavelength of the stationary phase ranges from 248 to 250 nm; the temperature of a sample chamber ranges from 4 to 10 degrees Celsius; and the initial volume ratio of the inorganic acid to the organic phase of the mobilephase ranges from (72:28) to (85:15). The method of the invention can simultaneously separate and quantitatively measure three kinds of sulfonamide-class impurities, namely, sulfonamide, 4-SAPH and YF042-14 in celecoxib and chemical medicines containing sulfonamide-class impurities without being interfered, has a good peak pattern, and can completely and effectively control the quality of the celecoxib raw material. The method has the advantages of high specificity, high sensitivity and good accuracy.

The invention discloses a rapid nitrate detection reagent and a detection method. The rapid nitrate detection reagent includes a reagent I and a reagent II. The reagent I is composed of the followingcomponents by mass: 58-88.5% of organic acid, 1-10% of cadmium powder, 0.5-2% of sulfonamide and 10-30% of polyvinyl pyrrolidone. The reagent II is composed of the following components by mass: 2-6% of N-(1-naphthyl) ethylenediamine dihydrochloride and 94-98% of organic acid. The on-site rapid nitrate detection method of the invention includes the following steps: (1) adding a water sample under test to a colorimetric bottle, and then, adding the rapid nitrate detection reagent of the invention for developing; and (2) comparing the color with a standard colorimetric card or drawing a standardcurve to obtain the nitrate content of the water sample under test. The rapid nitrate detection reagent of the invention has strong adaptability and good stability, and can be used together with a standard colorimetric card or a portable colorimeter to rapidly determine the content of nitrate in water and food samples on site.

A pharmaceutical composition for application to an area of skin of a subject for local and/or systemic treatment of a COX-2 mediated disorder comprises a backing sheet that is flexibly conformable to the area of skin, the backing sheet having opposing surfaces that are respectively distal and proximal to the skin when applied; and a coating on the proximal surface of the backing sheet that comprises (a) an adhesive, (b) an active agent comprising a selective COX-2 inhibitory sulfonamide drug of low water solubility, and (c) a solvent system for the active agent, wherein the active agent is in a therapeutically effective total amount and the solvent system is selected with regard to composition and amount thereof to be effective to maintain the active agent substantially completely in solubilized form. A method of local treatment of a site of pain and/or inflammation in a subject comprises applying the composition to a skin surface of the subject, preferably at a locus overlying or adjacent to the site of pain and/or inflammation, and leaving the composition in place for a time period effective to permit delivery of a locally therapeutic amount of the active agent. A method of systemic treatment of a subject having a COX-2 mediated disorder comprises applying the composition to a skin surface of the subject, and leaving the composition in place for a time period effective to permit transdermal delivery of a therapeutic amount of the active agent.

The invention belongs to the field of chemical production, and provides a method for continuously preparing acesulfame potassium through a micro-channel reactor. The method comprises the following steps: enabling an acetoacetamido sulfonic acid triethylamine salt solution and a cyclizing agent continuously to enter the micro-reactor through interfaces A and B of the micro-reactor; after full reaction of the mixing section and the reaction section, carrying out full mixing reaction with water continuously entering from the interface C in the same reactor through the mixing section and the reaction section to obtain a reaction solution of acesulfamic acid from the outlet D, and carrying out separation processes such as continuous extraction, continuous neutralization, continuous concentration and continuous drying to obtain acesulfame potassium. The DKA solution, the cyclizing agent and the water are subjected to continuous cyclization and hydrolysis processes in the same micro-reactor;by changing and combining the mixing section and the reaction section of the micro-reactor, the ratio of cyclization and hydrolysis raw materials is adjusted, the temperature of reaction materials inthe micro-reactor and the residence time of the reaction materials in the mixing and reaction sections are controlled, and the side reaction is reduced by utilizing internal strong heat exchange.